MARINOMED BIOTECH AG INH.
MARINOMED BIOTECH AG INH./ ATMARINOMED6 /
93Z
9/4/2024 10:59:24 PM
|
Chg.
-0.300
|
Volume |
Bid10:59:24 PM |
Ask10:59:24 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
4.720EUR
|
-5.98%
|
- Turnover: - |
4.720Bid Size: - |
5.640Ask Size: - |
8.23 mill.EUR |
- |
- |
Business description
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide.
Management board & Supervisory board
CEO |
Andreas Grassauer |
Management board |
Pascal Schmidt, Eva Prieschl-Grassauer |
Supervisory board |
Simon Nebel, Brigitte Ederer, Elisabeth Lackner, Ulrich Kinzel, Eva Hofstaedter-Thalmann |
Company data
Name: |
Marinomed Biotech AG |
Address: |
Hovengasse 25,A-2100 Korneuburg |
Phone: |
+43-2262-90300 |
Fax: |
- |
E-mail: |
office@marinomed.com
|
Internet: |
https://www.marinomed.com/de/ |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12/31 |
Free Float: |
- |
IPO date: |
2/1/2019 |
Investor relations
Name: |
Stephanie Kniep |
IR phone: |
- |
IR Fax: |
- |
IR e-mail: |
ir@marinomed.com
|
Company calendar
CW 47 | 11/21/2024
Interim Report 3rd Quarter/9 Months
|